CTRI/2021/03/032103已完成4 期
An Open Label, Prospective, Randomized, Comparative, Multicenter and Phase IV Clinical Study to Evaluate the Efficacy and Safety of Fixed Dose Combination of Glimepiride plus Voglibose plus Metformin Tablets in Patients with Type 2 Diabetes Mellitus.
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 入组人数
- 355
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1. Male or Female Patients aged between 18 to 65 years (both inclusive).
- •2. Patients with confirmed documented diagnosis of type 2 diabetes mellitus.
- •3. Patients, along with diet and exercise control, additionally on treatment with stable daily dose of Metformin 1000 mg for at least 3 months prior to screening and having inadequate glycemic control at screening defined as HbA1c levels between ââ?°Â¥ 8.0 to ââ?°Â¤ 10.0%.
- •4. Patients with fasting blood glucose ââ?°Â¤ 270 mg/dL at screening visit.
- •5. Patients with postprandial blood glucose (2 hours post meal) concentration > 200 mg/dL at screening visit.
- •6. Women of childbearing potential (WOCBP) must be using an acceptable method of contraception to avoid pregnancy throughout the study. WOCBP must have a negative urine pregnancy test at screening / baseline visit.
- •7. Patient with ability to understand and provide written informed consent form, which must have been obtained prior to screening.
- •8. Patients willing to comply with the protocol requirements.
排除标准
- •1. Patients with intolerance, contraindication or potential allergy/hypersensitivity to any of the ingredients of study medication or drugs of similar class.
- •2. Patients with a history of Type 1 diabetes mellitus or secondary diabetes mellitus or diabetes insipidus.
- •3. Patients with a history of metabolic acidosis or diabetic ketoacidosis.
- •4. Patients with the Body Mass Index (BMI) < 18.5 and / or > 29.9 kg/m2 at screening visit.
- •5. Patients with Estimated glomerular filtration rate (eGFR) <60 mL/min/1.73 m2 [using the Modification of Diet in Renal Disease (MDRD) equation] at screening.
- •6. Patients with clinically significant impaired hepatic function (SGOT & SGPT more than 3X the UNL and/or Total bilirubin more than 1.5X the UNL) at screening.
- •7. Patients receiving Miconazole.
- •8. Patients with a history of congestive heart failure defined as New York Heart Association (NYHA) class III/IV, unstable or acute congestive heart failure.
- •9. Patients with significant cardiovascular history defined as: myocardial infarction, unstable angina pectoris, transient ischemic attack, unstable or previously undiagnosed arrhythmia, cardiac surgery or revascularization (coronary angioplasty or bypass grafts), or cerebrovascular accident.
- •10. Patients with uncontrolled hypertension with sitting systolic BP ââ?°Â¥ 160 mmHg and/or diastolic BP ââ?°Â¥ 100 mmHg at screening.
- •11. Any abnormality on 12-lead ECG at screening that in the opinion of the investigator is clinically significant and is judged as potential risk for patientââ?¬•s participation in the study.
- •12. Patients with a history of anaemia or haemoglobinopathy and/or haemoglobin < 10 g/dL for men; haemoglobin < 9 g/dL for women at screening.
- •13. Pregnant or breast-feeding, or expecting to conceive within the projected duration of the study.
- •14. Female patients who are of childbearing potential and who are neither surgically sterilized nor willing to use reliable contraceptive methods (like hormonal, barrier methods or intrauterine device).
- •15. Patients with known case of infection with hepatitis B, hepatitis C or HIV.
- •16. Patients with donation or transfusion of blood, plasma, or platelets within the past 3 months prior to screening.
- •17. Patients with a history of substance abuse or dependence that in the opinion of the Investigator is considered to interfere with the patientââ?¬•s participation in the study.
- •18. Patients with concurrent participation in another clinical trial or any investigational therapy within 90 days prior to signing informed consent.
- •19. Patients currently taking any of the prohibited medications(s) and inability/unwillingness to discontinue them for the entire study period.
- •20. Patient with any condition which, in the judgment of the Investigator, may render the patient unable to complete the study or which may pose a significant risk to the patient.
研究者
相似试验
已完成
不适用
To Compare and Evaluate the Effect of Duchenne Muscular Dystrophy affected Patients Undergoing Current TreatmentAlong with Food SupplementsCTRI/2021/05/033346ichiIn Biosciences Pvt Ltd28
尚未招募
不适用
To Compare and Evaluate the Effect of Corona affected Patients Undergoing Current Treatment Along with Food SupplementsCTRI/2021/04/032766ichiIn Biosciences Pvt Ltd
尚未招募
3 期
Clinical Study on Nichi Glucan to Verify Effectiveness on Covid19CTRI/2021/10/037380ichiIn Bio Sciences Pvt Ltd
已完成
不适用
Clinical Study on ââ?¬Å?Herbecht Hair Oilââ?¬? on Hair Fall and Premature Graying.CTRI/2021/10/037684Mr Dileep Kumar30
招募中
3 期
Study on Nutritional Supplement for Diabetic Patients.CTRI/2022/08/045041ichiIn Bio Sciences Pvt Ltd